Company Description
ETHZilla Corporation, a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States.
The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren’s Contracture; and Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain.
The company was formerly known as 180 Life Sciences Corp. and changed its name to ETHZilla Corporation in August 2025.
ETHZilla Corporation is headquartered in Palm Beach, Florida.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | McAndrew Rudisill |
Contact Details
Address: 2875 South Ocean Blvd, Suite 200 Palm Beach, Florida 33480 United States | |
| Phone | 650 507 0669 |
| Website | ethzilla.com |
Stock Details
| Ticker Symbol | ETHZ |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001690080 |
| CUSIP Number | 68236V104 |
| ISIN Number | US68236V3024 |
Key Executives
| Name | Position |
|---|---|
| Lloyd Blair Jordan L.L.B., M.B.A. | Co-Founder, Chief Executive Officer and Director |
| McAndrew Rudisill BA(Econ) | Executive Chairman |
| Eric R. Van Lent | Principal Accounting and Financial Officer |